Saryah Azmat

Ms. Azmat leads business development, corporate strategy, and capital formation at Turnstone. Her contributions and leadership have been critical to the growth of the business, including Turnstone’s recent acquisition of Myst Therapeutics and ongoing investor relations activities. Ms. Azmat joined Turnstone from Bristol-Myers Squibb (“BMS”), where she was the Global Lead for Oncology Search & Evaluation. During her six-year tenure at BMS, Ms. Azmat executed over 15 major transactions spanning all stages of preclinical and clinical development. Prior to BMS, she was a consultant for global biopharma clients at Putnam Associates, where she managed clinical and commercial stage projects. Ms. Azmat earned a B.A. in engineering sciences and a B.E. in biomedical engineering from the Thayer School of Engineering at Dartmouth College.